CD36 expression and its relationship with obesity in blood cells from people with and without Prader-Willi syndrome

Clinical Genetics

Volumn 69, Issue 1, 2006, Pages 26-32

  Webb, T ^a,e   Whittington, J ^b   Holland, A J ^b   Soni, S ^b   Boer, H ^c   Clarke, D ^c   Horsthemke, B ^d  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c Department for Children Young People and Their Families   (United Kingdom)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e BIRMINGHAM WOMEN S HOSPITAL   (United Kingdom)

Author keywords

CD36; Expression; Obesity; Prader Willi syndrome

Indexed keywords

CD36 ANTIGEN; GLUCOSE; LIPID;

ADULT; ARTICLE; BODY MASS; CHROMOSOME 7Q; CHROMOSOME MAP; CHROMOSOME MOSAICISM; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; FEMALE; GENE EXPRESSION; GLUCOSE HOMEOSTASIS; HUMAN; HUNGER; LIPID METABOLISM; MALE; OBESITY; PATHOGENESIS; PRADER WILLI SYNDROME; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; UNIPARENTAL DISOMY;

ADULT; ANTIGENS, CD36; BODY MASS INDEX; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; OBESITY; POLYMERASE CHAIN REACTION; PRADER-WILLI SYNDROME; UNIPARENTAL DISOMY;

EID: 33644870747     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2006.00536.x     Document Type: Article

References (30)

1. Nicholls RD. Genomic imprinting and candidate genes in the Prader-Willi and Angelman syndromes. Curr Opin Genet Dev 1993: 3: 445-456.
2. Holland AJ, Whittington JE, Butler J, Webb T, Boer H, Clarke D. Behavioural phenotypes associated with specific genetic disorders: evidence from a population based study of people with Prader-Willi syndrome. Psychol Med 2003: 33: 141-153.
3. Horsthemke B, Nazlican H, Husing J et al. Somatic mosaicism for maternal uniparental disomy 15 in a girl with Prader-Willi syndrome: Confirmation by cell cloning and identification of candidate downstream genes. Hum Mol Genet 2003: 12: 2723-2732.
4. Savill J, Hogg N, Ren Y, Haslett C. Thrombospondin cooperates with CD36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis. J Clin Invest 1992: 90: 1513-1522.
5. Tandon NN, Lipsky RH, Burgess WH, Jamieson GA. Isolation and characterization of platelet glycoprotein IV (CD36). J Biol Chem 1989: 264: 7570-7575.
6. Silverstein RL, Asch AS, Nachman RL. Glycoprotein IV mediates thrombospondin-dependent platelet-monocyte and platelet-U937 cell adhesion. J Clin Invest 1989: 84: 546-552.
7. Oquendo P, Hundt E, Lawler J, Seed B. CD36 directly mediates cytoadherence of Plasmodium falciparum parasitized erythrocytes. Cell 1989: 58: 95-101.
8. Rosen ED, Spiegelman BM. PPARγ a nuclear regulator of metabolism, differentiation and cell growth. J Biol Chem 2001: 276: 37731-37734.
9. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med 2004: 10: 1-7.
10. Ristow M, Muller-Wieland D, Pfeiffer A, Krone W, Kahn CR. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med 1998: 339: 953-959.
11. Griffin E, Re A, Hamel N et al. A link between diabetes and atherosclerosis: Glucose regulates expression of CD36 at the level of translation. Nat Med 2001: 7: 840-846.
12. Febbraio M, Guy E, Coburn C et al. The impact of over expression and deficiency of fatty acid translocase. (FAT)/Cd36. Mol Cell Biochem 2002: 239: 193-197.
13. Hirano K, Kuwasako T, Nakagawa-Toyama Y, Janabi M, Yamashita S, Matsuzawa Y. Pathophysiology of human genetic CD36 deficiency. Trends Cardiovasc Med 2003: 13: 136-141.
14. Linton MF, Fazio S. Macrophages, inflammation and atherosclerosis. Int J Obes Relat Metab Disord 2003: 27 (Suppl. 3): S35-S40.
15. Whittington J, Holland A, Webb T, Butler J, Clarke D, Boer H. Relationship between clinical and genetic diagnosis of Prader-Willi syndrome. J Med Genet 2002: 39: 926-932.
16. Kubota T, Das S, Christian SL, Baylin SB, Herman JG, Ledbetter DH. Methylation-specific PCR simplifies imprinting analysis. Nat Genet 1997: 16: 16-17.
17. Zeschnigk M, Lich C, Buiting K, Doerfler W, Horsthemke B. A single-tube PCR test for the diagnosis of Angelman and Prader-Willi syndrome based on allelic methylation differences at the SNRPN locus. Eur J Hum Genet 1997: 5: 94-98.
18. Gertow K, Pietilainen KH, Yki-Jarvinen H et al. Expression of fatty-acid-handling proteins in human adipose tissue in relation to obesity and insulin resistance. Diabetologia 2004: 47: 1118-1125.
19. Fisher RM, Hoffstedt J, Hotamisligil GS, Thorne A, Ryden M. Effects of obesity and weight loss on the expression of proteins involved in fatty acid metabolism in human adipose tissue. Int J Obes Relat Metab Disord 2002: 26: 1379-1385.
20. Ramis JM, Franssen-van Hal NL, Kramer E et al. Carboxypeptidase E and thrombospondin-1 are differently expressed in subcutaneous and visceral fat of obese subjects. Cell Mol Life Sci 2002: 59: 1960-1971.
21. Coburn CT, Knapp FF, Febbraio M, Beets AL, Silverstein RL, Abumradi NA. Defective uptake and utilization of long chain fatty acids in muscle and adipose tissue of CD36 knockout mice. J Biol Chem 2000: 275: 32523-32529.
22. Bell CG, Walley AJ, Froguel P. The genetics of human obesity. Nature Rev Genet 2005: 6: 221-234.
23. Corcoran L, Vremec D, Febbraio M, Baldwin T, Handman E. Differential regulation of CD36 expression in antigen-presenting cells: Oct-2 dependence in B lymphocytes but not dendritic cells or macrophages. Int Immunol 2002: 14: 1099-1104.
24. Aitman TJ, Glazier AM, Wallace CA et al. Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. Nat Genet 1999: 21: 76-83.
25. Brinkmann JFF, Abumrad NA, Ibrahim A, Van der Vusse GJ, Glatz FC. New insights into long-chain fatty acid uptake by heart muscles: A crucial role for fatty acid translocase/CD36. Biochem J 2002: 367: 561-570.
26. Yanai H, Chiba H, Fujiwara H et al. Metabolic changes in human CD36 deficiency displayed by glucose loading. Throm Haemost 2001: 86: 995-999.
27. Schuster DP, Osei K, Zipf WB. Characterisation of alterations in glucose and insulin metabolism in Prader-Willi subjects. Metabolism 1996: 45: 1514-1520.
28. Butler MG, Carlson MG, Schmidt DE, Feurer ID, Thompson T. Plasma cholecystokinin levels in Prader-Willi syndrome and obese subjects. Am J Med Genet 2000: 95: 67-70.
29. Holland AJ, Whittington JE, Hinton EC. The paradox of Prader-Willi syndrome: A genetic model of starvation. Lancet 2003: 362: 989-991.
30. Horn CC, Friedman MI. Etomoxir, a fatty acid oxidation inhibitor, increases food intake and reduces hepatic energy status in rats. Physiol Behav 2004: 81: 157-162.